Post by Symeres

What's changing in ADME-Tox in 2026? Almost everything. As drug discovery moves into peptides, oligonucleotides, PROTACs and ADCs, the rules of “what good data looks like” are changing. CYP metabolism, permeability screens, and classic clearance models made sense for small molecules. But newer modalities operate differently. This is forcing a rethink across the field: • Oligonucleotides: liver/kidney-driven distribution, not CYP metabolism • Peptides: rapid degradation and low oral bioavailability • PROTACs: size + mechanism complexity that breaks classic PK/PD assumptions • ADCs: linker + payload + antibody all shaping ADME outcomes differently Meanwhile, two bigger trends are changing the entire discipline: 👉 AI/ML models trained on increasingly diverse datasets 👉 Complex in vitro systems reducing reliance on traditional in vivo studies The future of ADME-Tox isn’t about replacing old tools — it’s about expanding the framework to match the biology we’re now working with. 🔗 If you’re working with emerging modalities, this breakdown explores how ADME-Tox strategies, models, and interpretation approaches are evolving alongside them: https://brnw.ch/21x3ijf